 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- || Review, Journal: Quintessence of currently approved and upcoming treatments for dry eye disease. (Pubmed Central) - Feb 27, 2025
Currently, the US Food and Drug Administration (FDA)-approved medical treatments for treatment of DED include cyclosporine formulations (RESTASIS
- | licaminlimab (OCS-02) / Oculis
Biomarker, Journal: Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor ? Antagonist Licaminlimab (OCS-02) in Dry Eye Disease: Retraction. (Pubmed Central) - Sep 3, 2024
Currently, the US Food and Drug Administration (FDA)-approved medical treatments for treatment of DED include cyclosporine formulations (RESTASIS No abstract available
- | licaminlimab (OCS-02) / Oculis
Biomarker, Journal: Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor ? Antagonist Licaminlimab (OCS-02) in Dry Eye Disease. (Pubmed Central) - Feb 28, 2024
The CC genotype of rs1800693, relatively common in patients with DED, was strongly associated with response to licaminlimab and decreased inflammatory cytokine gene expression in ocular surface cells during treatment. This study is one of the first to our knowledge to investigate pharmacogenomics in the treatment of DED.
- || licaminlimab (OCS-02) / Oculis
Enrollment closed: RELIEF: Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease (clinicaltrials.gov) - Feb 5, 2024
P2, N=120, Active, not recruiting, Sponsor: Oculis
This study is one of the first to our knowledge to investigate pharmacogenomics in the treatment of DED. Recruiting --> Active, not recruiting
- ||| licaminlimab (OCS-02) / Oculis
Enrollment open: RELIEF: Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease (clinicaltrials.gov) - Dec 8, 2023
P2, N=120, Recruiting, Sponsor: Oculis
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || licaminlimab (OCS-02) / Oculis
Trial initiation date, Trial primary completion date: RELIEF: Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease (clinicaltrials.gov) - Nov 28, 2023
P2, N=120, Not yet recruiting, Sponsor: Oculis
Not yet recruiting --> Recruiting Initiation date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2024 --> May 2024
- |||| licaminlimab (OCS-02) / Oculis
New P2 trial: RELIEF: Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease (clinicaltrials.gov) - Jun 9, 2023
P2, N=120, Not yet recruiting, Sponsor: Oculis
- || OCS-02 / Oculis
Clinical, P2 data: Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study. (Pubmed Central) - Jul 14, 2022
Serum licaminlimab was undetectable in most patients; the maximum concentration observed was 8.47 ng/mL. Topical ocular licaminlimab demonstrated statistically significant improvement in global ocular discomfort score compared to Vehicle in patients with severe DED, with good tolerability, no increase in IOP, and minimal systemic drug exposure.
- | licaminlimab (OCS-02) / Oculis
Trial completion: Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis (clinicaltrials.gov) - Apr 6, 2016
P2, N=46, Completed, Sponsor: Alcon Research
Topical ocular licaminlimab demonstrated statistically significant improvement in global ocular discomfort score compared to Vehicle in patients with severe DED, with good tolerability, no increase in IOP, and minimal systemic drug exposure. Active, not recruiting --> Completed
- | licaminlimab (OCS-02) / Oculis
Enrollment closed: Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis (clinicaltrials.gov) - Mar 18, 2016
P2, N=46, Active, not recruiting, Sponsor: Alcon Research
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| licaminlimab (OCS-02) / Oculis
Trial completion, Enrollment change: LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease (clinicaltrials.gov) - Oct 29, 2015
P2, N=514, Completed, Sponsor: Alcon Research
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=380 --> 514
- ||| licaminlimab (OCS-02) / Oculis
Enrollment closed: LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease (clinicaltrials.gov) - Aug 13, 2015
P2, N=380, Active, not recruiting, Sponsor: Alcon Research
Active, not recruiting --> Completed | N=380 --> 514 Recruiting --> Active, not recruiting
- | licaminlimab (OCS-02) / Oculis
New P2 trial: Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis (clinicaltrials.gov) - Jun 26, 2015
P2, N=40, Recruiting, Sponsor: Alcon Research
- |||| licaminlimab (OCS-02) / Oculis
Enrollment open: LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease (clinicaltrials.gov) - Mar 21, 2015
P2, N=380, Recruiting, Sponsor: Alcon Research
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| licaminlimab (OCS-02) / Oculis
New P2 trial: LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease (clinicaltrials.gov) - Feb 19, 2015
P2, N=380, Not yet recruiting, Sponsor: Alcon Research